Our dedicated teams at FutureMeds Madrid, Seville, and Cadiz, led by Principal Investigator Dr Ana Maria Moreno alongside sub-investigators Dr Miguel Genebat (Seville) and Dr Antonio Clavo (Cadiz), have emerged as top recruiters worldwide for a phase 2a/b celiac disease trial.
FutureMeds Spain has emerged as the top recruiter worldwide in an ongoing Phase 2a/b clinical trial investigating an innovative treatment for non-responsive celiac disease.
Led by Principal Investigator Dr Ana Maria Moreno alongside sub-investigators Dr Miguel Genebat (Sevilla) and Dr Antonio Clavo (Cádiz), our dedicated teams at FutureMeds Madrid, Sevilla, and Cádiz, in collaboration with Viamed Salud, have demonstrated exceptional commitment to expanding patient access to new treatment opportunities.
“I am proud to lead this trial, in which both my colleagues in Sevilla and Cádiz and I are working hard to provide our patients with new treatment opportunities. Additionally, collaboration with patient associations in different regions is helping to spread awareness about this opportunity among those who are suffering from the symptoms of this condition. This collective effort not only enhances our research but also connects us directly with the communities in need, enabling us to make a meaningful impact in their lives.”
— Dr. Ana Maria Moreno, Principal Investigator
With 72% of planned sites now active across 19 countries and with a strong January and February performance, the trial is now making confident progress towards its randomisation target. We take pride in our Spanish teams, who have been instrumental in helping our client make progress.
“The significance of reaching patients across Spain, particularly in regions like Cádiz where access to innovative treatments can be more challenging than in major metropolitan areas, highlights our commitment to addressing healthcare disparities while advancing medical research.”
— Rocio Diaz Sanchez, Managing Director at FutureMeds Spain
In their latest newsletter, the client has recognised Dr Ana Maria Moreno and the FutureMeds Spain team’s performance.
This achievement not only highlights the team’s efforts to provide new therapeutic options but also emphasises our dedication to addressing healthcare disparities within the country.
“Successfully treating even a single patient can serve as a catalyst for further research, raise awareness about celiac disease, and potentially lead to more inclusive health strategies for underserved areas,” added Rocio Diaz Sanchez.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.
Comentários